Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Person › Details

Marceline Clementine (Trophos S.A.)

Clementine, Marceline (Trophos 201209– appointed CFO joint Trophos in 2006)

 

Organisation Organisation Trophos S.A.
  Group Roche (Group)
Products Product olesoxime
  Product 2 TRO40303
     

Trophos S.A.. (9/18/12). "Press Release: Marceline Clementine Appointed Chief Financial Officer". Marseille.

Trophos SA, a French pharmaceutical company developing innovative therapies in neurology and cardiology up to the clinical validation stage, announces today the appointment of Marceline Clementine as chief financial officer.

Marceline Clementine has more than 30 years experience in the world of finance. She joined Trophos in 2006 as administration and finance manager. Before that, she had worked as chief accountant or financial controller at various companies in the real estate and catering sectors, including Groupe FLO.

She is now responsible for all administrative and financial services at Trophos, as well as for human resources management. Marceline Clementine succeeds Christine Placet, the former chief financial officer, who has just been promoted to the post of chief executive officer of Trophos.

"We are delighted to welcome Marceline Clementine as chief financial officer," said Christine Placet, the CEO of Trophos. "This appointment is a recognition of Ms. Clementine's competence in financial matters and her strong commitment to Trophos over the past few years. Her financial management skills are a precious asset for the company. We are continuing our quest to find strategic partners for our current programs to guarantee the future of our company, which was founded 13 years ago now."

Trophos has sufficient funding in hand to continue its research activities up to 2014. The company is currently undertaking several programs focused on the following drug candidates:

- Olesoxime in Spinal Muscular Atrophy (SMA): a pivotal study is underway and the results are expected in the second half of 2013.

- Olesoxime for multiple sclerosis (MS) disease progression: a phase II proof-of-concept study has been designed in conjunction with international MS specialists.

- TRO40303 cardiac protection compound: a phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI) is underway and the results are expected in the first half of 2013.


About Trophos SA - http://www.trophos.com

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in a pivotal clinical study for Spinal Muscular Atrophy (substantially funded by the AFM patient association). Olesoxime is also ready for a phase II proof of concept study in Multiple Sclerosis (MS) disease progression. A second product, TRO40303, is in phase II clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare). Trophos' mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs, which Trophos is uniquely placed to exploit.

Trophos, founded in 1999, is based in Marseille, France and currently has 27 employees.


For further information, please contact:

Andrew Lloyd & Associates
Andrew Lloyd - Céline Gonzalez
Tel: +33 1 56 54 07 00
allo@ala.com / celine@ala.com


   
Record changed: 2015-08-27

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px


More documents for Marceline Clementine


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top